Prompt Approval of Safe Generic Drugs Act

This bill amends the Federal Food, Drug, and Cosmetic Act to clarify that generic drug applications (submitted under sections 505(b)(2) or 505(j)) cannot be delayed or rejected solely because safety information (like warnings or contraindications) is omitted from labeling - provided that information is protected by patent, exclusivity, or an extension of exclusivity. It requires the FDA to add necessary safety statements to labeling for such drugs to ensure safe use. The bill directly affects generic drug manufacturers and the FDA’s approval process, ensuring safety-related exclusivity does not block timely generic drug access. It does not alter existing exclusivity periods or other labeling requirements.